- CA$26.68m
- CA$18.40m
- CA$19.31m
- 45
- 84
- 36
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.96 | ||
| Price to Tang. Book | 6.87 | ||
| Price to Free Cashflow | 3.64 | ||
| Price to Sales | 0.87 | ||
| EV to EBITDA | 12.51 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 4.04% | ||
| Return on Equity | -5.44% | ||
| Operating Margin | 1.81% | ||
Financial Summary
| Year End 31st Jul | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 2.14 | 1.47 | 2.31 | 2.35 | 19.31 | n/a | n/a | 26.59% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Devonian Health Group Inc. is a Canada-based late-stage botanical pharmaceutical company. The Company is focused on developing prescription botanical drugs from plant materials and algae for the treatment of inflammatory autoimmune diseases, including but not limited to ulcerative colitis and atopic dermatitis. It is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health conditions related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., is focused on selling prescription pharmaceutical products in Canada, under license from brand name pharmaceutical companies.
Directors
- Last Annual
- July 31st, 2024
- Last Interim
- January 31st, 2025
- Incorporated
- May 12th, 2017
- Public Since
- September 9th, 2014
- No. of Employees
- 6
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 148,222,532
- Address
- 360 rue des Entrepreneurs, MONTMAGNY, G5V 4T1
- Web
- https://groupedevonian.com/
- Phone
- +1 5142487509
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for GSD
Similar to GSD
Aequus Pharmaceuticals
TSX Venture Exchange
Arch Biopartners
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Cytophage Technologies
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
FAQ
What is the Devonian Health share price?
As of Today at 20:14 UTC, shares in Devonian Health are trading at CA$0.18. This share price information is delayed by 15 minutes.
How has the Devonian Health share price performed this year?
Shares in Devonian Health last closed at CA$0.18 and the price had moved by -28% over the past 365 days. In terms of relative price strength the Devonian Health share price has underperformed the Toronto Stock Exchange 300 Composite Index by -35.99% over the past year.
What are the analyst and broker recommendations for Devonian Health?
There is no consensus recommendation for this security.
Find out moreWhat is the Devonian Health dividend yield?
Devonian Health does not currently pay a dividend.
Does Devonian Health pay a dividend?
Devonian Health does not currently pay a dividend.
When does Devonian Health next pay dividends?
Devonian Health does not currently pay a dividend.
How do I buy Devonian Health shares?
To buy shares in Devonian Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Devonian Health?
As of the previous close price of CA$0.18, shares in Devonian Health had a market capitalisation of CA$26.68m.
Where are Devonian Health shares listed?
Here are the trading details for Devonian Health:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: GSD
What kind of share is Devonian Health?
Based on an overall assessment of its quality, value and momentum Devonian Health is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Devonian Health share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Devonian Health share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Devonian Health. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +11.84%.
As of the last closing price of CA$0.18, shares in Devonian Health were trading -4.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Devonian Health PE Ratio?
The Devonian Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Devonian Health?
We do not have data on Devonian Health's directors